M. Javle et al. analyzed, in a retrospective cohort, the efficacy of ERBB2-directed therapy for 14 patients with ERBB2 amplification or overexpression suffering from gallblader cancer or cholangiocarcinoma. Here, ERBB2 is linked to cholangiocarcinoma.